The immune checkpoint inhibitors of PD‐1/PD‐L1 (anti–PD‐1/PD‐L1) are currently changing the approach to treatment of patients with advanced non‐small cell lung cancer (NSCLC). This evidence concerns the gene CD274 and non-small cell lung carcinoma.